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levels on the MPQ compared to TE/I patients two-years postoperatively, an important point to consider during preoperative counseling. The presence of preoperative pain was also a risk factor for CPSP. While multiple studies in recent years have focused on the widespread and underreported prevalence of post-mastectomy CPSP, only 10% of the sample had moderate-to-severe pain at two years. Therefore, approximately 90% were either pain-free or living with a level of pain that would not be expected to interfere with daily function. Overall, our data suggest that CPSP for this cohort may be of less clinical concern than previously described, and reports of persistent pain after breast reconstruction may not necessarily reflect surgery-induced pain. 
The Effect of Intraoperative

METHODS:
A prospective, randomized, doubleblinded, placebo-controlled, clinical trial was conducted in which patients undergoing immediate TE/I breast reconstruction were randomized to either: 1) intraoperative intercostal and pectoral nerve blocks with 0.25 % bupivacaine with 1:200,000 epinephrine and 4 mg dexamethasone or 2) sham nerve blocks with normal saline. Surgeon, patient and researchers collecting postoperative data were blind to group allocation. Quality of recovery (QoR 40), pain score, and opioid use in the postoperative period were compared between groups using the Mann-Whitney's U test. Fisher's exact test was used between categorical variables. Power analysis ensured 80% power to detect a 10-point (clinically significant) difference in QoR 40.
RESULTS: 47 patients were enrolled. Age, BMI, laterality, mastectomy type, and lymph node dissection were similar between groups. There were no statistical differences in quality of recovery, pain burden as measured by visual analog scale, or opioid consumption between groups at 24 hours following surgery. Mean global QoR scores were 169 (range: 155-182) for the treatment arm and 165 (range: 143 to 179) for the placebo arm (p = 0.36), indicating a relatively high quality of recovery in both groups. There was less total narcotic required by the treatment group compared to placebo in both PACU (8 v. 17 morEq, p = 0.26) and on the inpatient unit (92 vs. 114, p = 0.31), though these differences were not statistically or clinically significant. Ten patients in the placebo group and six patients in the treatment group required anti-emetic use postoperatively, P= 0.56. Length of hospital stay averaged 1 day in both groups. There were no adverse events or injectionrelated complications.
CONCLUSION:
While intraoperative nerve blocks can be a safe and effective adjunct to a comprehensive post-surgical recovery regimen, our results indicate no difference in quality of recovery between patients who received intraoperative intercostal and pectoral nerve blocks with bupivacaine and dexamethasone compared to those who received sham placebo injections. 
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